Inovio Pharmaceuticals Inc (INO)

[mackwheaton]

I believe INO is the real deal and that they wii receive increasingly lucrative partnership agreements. Their ability to turn out vaccines in such incredibly short time frames will create a problem, though a good one; when that first caller comes knocking and offers $2.5 billion for the whole company, will they take it or will they remain independent? Who is going to turn down $10 per share, and what big pharma would not view that as a drop in the bucket to acquire not only the inventory, but the technology and the human resources. I believe that will be the most difficult question Kim will encounter in the next 18 months.